{"entity":{"id":"risk-reducing-salpingectomy","kind":"technology","name":"Risk-reducing and opportunistic salpingectomy","aka":[],"tldr":"Removing the fallopian tubes, where most ovarian cancer starts, during other pelvic surgery or in women at inherited risk.","summary":"Because high-grade serous cancer originates in the tubal fimbria, removing the tubes at hysterectomy or instead of tubal ligation (opportunistic salpingectomy) is recommended by ACOG and SGO for average-risk women. In BRCA carriers, salpingo-oophorectomy by age 35-45 remains standard; salpingectomy with delayed oophorectomy (TUBA-WISP II, SOROCk) is under study to postpone surgical menopause. Population data from British Columbia show falling incidence after policy adoption.","status":"established","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Salpingectomy","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Salpingectomy"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":["prevention","surgery"],"technologies":["chemoprevention"],"targets":["brca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["hgsoc"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Removing the fallopian tubes eliminates the tissue of origin of high-grade serous carcinoma while sparing ovarian hormone production.","strengths":["Prevents the ovarian cancer type with the lowest survival without hormonal consequences","Adds little time or risk to existing surgery"],"limitations":["Does not prevent non-tubal ovarian cancers","Benefit for BRCA carriers versus oophorectomy still unproven"]},"route":"/technologies/risk-reducing-salpingectomy/","neighbours":{"cancer":[{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"},{"id":"surgery","kind":"section","name":"Surgery & Interventional","route":"/fronts/surgery/"}],"technology":[{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"}],"term":[{"id":"hereditary-cancer-syndromes","kind":"term","name":"Hereditary cancer syndromes","route":"/terms/hereditary-cancer-syndromes/"},{"id":"hgsoc","kind":"term","name":"High-grade serous ovarian carcinoma (HGSOC)","route":"/terms/hgsoc/"}],"person":[{"id":"angelina-jolie","kind":"person","name":"Angelina Jolie","route":"/people/angelina-jolie/"}],"bottleneck":[{"id":"b-hereditary-risk","kind":"bottleneck","name":"Inherited risk is mostly unidentified","route":"/bottlenecks/b-hereditary-risk/"}],"roadmap":[{"id":"prevention-roadmap","kind":"roadmap","name":"Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers","route":"/roadmaps/prevention-roadmap/"},{"id":"cure-paths","kind":"roadmap","name":"Paths to cures: interception, eradication, control","route":"/roadmaps/cure-paths/"}],"collection":[{"id":"ovarian-cancer-research-alliance","kind":"collection","name":"Ovarian Cancer Research Alliance (OCRA)","route":"/collections/ovarian-cancer-research-alliance/"}]}}